Skip to content

SION SION Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$1.86B

Returns & leverage

See full
Return on equity-26.7%
Debt / equity0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by SION in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SION's operating lease right-of-use asset amortization?
SION (SION) reported operating lease right-of-use asset amortization of $489K in Q1 2026.
How has SION's operating lease right-of-use asset amortization changed year-over-year?
SION's operating lease right-of-use asset amortization decreased by 0.4% year-over-year, from $491K to $489K.